NAFLD activity as well as ALT + AST concentrations increased from weeks 4–6 in the control groups but were stopped in their progression if ACBP/DBI was inhibited during the last 2 weeks of the experiment (Fig. 2C–E). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.